Notify me when Casdin Capital, LLC files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| LAB | Standard BioTools Inc. | Common Stock, $0.001 par value per share | 24% | $107,459,205 | +$14,465,243 | 93,442,787 | +16% | Eli Casdin | 25 Nov 2025 |
| BLFS | BioLife Solutions, Inc. | Common Stock, par value $0.001 per share | 12% | $151,967,279 | -$19,132,500 | 5,957,165 | -11% | Casdin Capital, LLC | 15 Oct 2025 |
| NGNE | Neurogene Inc. | Common Stock, $0.000001 par value | 8.7% | $19,961,513 | 1,295,361 | Casdin Capital, LLC | 31 Dec 2024 | ||
| TNYA | Tenaya Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 4.3% | $3,231,826 | 6,732,971 | Casdin Capital, LLC | 04 Mar 2025 | ||
| IPSC | Century Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 3.7% | $1,702,527 | 3,212,316 | Casdin Capital, LLC | 31 Mar 2025 | ||
| CDXS | Codexis, Inc. | Common Stock, par value $0.0001 per share | 0% | $0 | -$17,568,000 | 0 | -100% | CASDIN CAPITAL, LLC | 30 Sep 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|